Abstract:Discovering pathophysiologic networks in a blood-based approach may help to generate valuable tools for early treatment or preventive measures in autism. To date targeted or untargeted metabolomics approaches to identify metabolic features and pathways affecting fetal neurodevelopment have rarely been applied to pregnancy samples, that is, an early period potentially relevant for the development of autism spectrum disorders (ASD). We conducted a population-based study relying on autism diagnoses retrieved from California Department of Developmental Services record. After linking cases to and sampling controls from birth certificates, we retrieved stored maternal mid-pregnancy serum samples collected as part of the California Prenatal Screening Program from the California Biobank for children born 2004 to 2010 in the central valley of California. We retrieved serum for 52 mothers whose children developed autism and 62 population controls originally selected from all eligible children matched by birth year and child's sex. Also, we required that these mothers were relatively low or unexposed to air pollution and select pesticides during early pregnancy. We identified differences in metabolite levels in several metabolic pathways, including glycosphingolipid biosynthesis and metabolism, N-glycan and pyrimidine metabolism, bile acid pathways and, importantly, C21-steroid hormone biosynthesis and metabolism. Disturbances in these pathways have been shown to be relevant for neurodevelopment in rare genetic syndromes or implicated in previous studies of autism. This study provides new insight into maternal mid-pregnancy metabolic features possibly related to the development of autism and an incentive to explore whether these pathways and metabolites are useful for early diagnosis, treatment, or prevention. LAY SUMMARY: This study found that in mid-pregnancy the blood of mothers who give birth to a child that develops autism has some characteristic features that are different from those of blood samples taken from control mothers. These features are related to biologic mechanisms that can affect fetal brain development. In the future, these insights may help identify biomarkers for early autism diagnosis and treatment or preventive measures. Autism Res 2020, 13: 1258-1269. © 2020 International Society for Autism Research, Wiley Periodicals, Inc.

Urine metabolomic profiles of autism and autistic traits-A twin study

Urinary Untargeted Metabolic Profile Differentiates Children with Autism from Their Unaffected Siblings

Untargeted urine metabolomics and machine learning provide potential metabolic signatures in children with autism spectrum disorder

Altered Urinary Amino Acids in Children with Autism Spectrum Disorders.

Differential Metabolites in Chinese Autistic Children: A Multi-Center Study Based on Urinary 1H-NMR Metabolomics Analysis

Comparison of the Metabolic Profiles in the Plasma and Urine Samples Between Autistic and Typically Developing Boys: A Preliminary Study

Urinary proteome profiling for children with autism using data-independent acquisition proteomics

A Proteomic Analysis of Urine Biomarkers in Autism Spectrum Disorder

Unraveling the metabolomic architecture of autism in a large Danish population-based cohort

Integration of Urine Proteomic and Metabolomic Profiling Reveals Novel Insights into Neuroinflammation in Autism Spectrum Disorder

Biomarkers and pathways in autism spectrum disorder: An individual meta-analysis based on proteomic and metabolomic data

Urinary 3-(3-Hydroxyphenyl)-3-hydroxypropionic Acid, 3-Hydroxyphenylacetic Acid, and 3-Hydroxyhippuric Acid Are Elevated in Children with Autism Spectrum Disorders

Metabolomic profiles in Jamaican children with and without autism spectrum disorder

Using urine FTIR spectra to screen autism spectrum disorder

Altered Metabolic Characteristics in Plasma of Young Boys with Autism Spectrum Disorder

Urinary Metabolomic Profiling Reveals Biological Pathways and Predictive Signatures Associated with Childhood Asthma

Gut microbiome and serum amino acid metabolome alterations in autism spectrum disorder

Urinary organic acids spectra in children with altered gut microbiota composition and autistic spectrum disorder

Disordered Porphyrin Metabolism: A Potential Biological Marker for Autism Risk Assessment

Untargeted Metabolomics Screen of Mid-pregnancy Maternal Serum and Autism in Offspring

Reanalysis of metabolomics data reveals that microbiota transfer therapy modulates important fecal and plasma metabolite profiles in children with autism spectrum disorders